multidrug-resistant strains of Mycobacterium tuberculosis continue to threaten global tuberculosis control efforts. Currently, the foundation of treatment for persons with uncomplicated tuberculosis is a 6-month regimen that consists of 2 months of isoniazid, rifampin, ethambutol, and pyrazinamide therapy followed by 4 months of isoniazid and rifampin therapy. A series of clinical trials [3, 4] demonstrated this regimen's efficacy in curing 195% of adults with pulmonary tuberculosis; however, these trials were performed before the appearance of HIV infection.
Antituberculosis drug pharmacokinetics are known to be influenced by patient age, sex, and ethnicity; gastrointestinal infections and disorders; drug-drug interactions; and drug formulations [5] [6] [7] [8] . HIV infection, for reasons that are likely multifactorial, has also been associated with lower concentrations of antituberculosis drugs [9] [10] [11] [12] . Perhaps in part because of these differences, people with HIV infection who develop tuberculosis may also be at a higher risk of treatment failure, treatment default, tuberculosis recurrence, and death from tuberculosis, compared with HIV-uninfected patients with tuberculosis [13] [14] [15] . Irrespective of HIV status, potential sequelae of inadequate antituberculosis drug concentrations include prolonged infectiousness, increased risk of relapse and death, and the development of drug-resistant M. tuberculosis infection [16, 17] . Few studies [16] [17] [18] have prospectively assessed antituberculosis drug pharmacokinetics among persons with tuberculosis and HIV infection in relation to tuberculosis treatment outcomes-an association that may be important to tuberculosis control efforts in the era of HIV infection and AIDS. We sought to determine the frequency and clinical significance of low blood concentrations of isoniazid, rifampin, ethambutol, and pyrazinamide among persons who received a diagnosis of tuberculosis in Botswana, where an estimated 60%-86% of patients with tuberculosis are infected with HIV [19] [20] [21] .
METHODS

Participants and procedures.
This study was conducted by the Botswana/USA Tuberculosis Project (BOTUSA). Detailed participant criteria and study procedures are described elsewhere [22] . In brief, from June 1997 through June 2000, outpatients at Princess Marina Hospital's Extension 2 outpatient clinic in Gaborone who were aged 117 years were screened for participation in the study if they had recently received a diagnosis of pulmonary tuberculosis and had been receiving DOT for at least 7 days. Further eligibility for enrollment included having a history of cough for у2 weeks and abnormal chest radiographic findings, providing consent for HIV testing, and having either sputum smear microscopy results showing acidfast bacilli or sputum cultures positive for M. tuberculosis. HIV infection status was determined by 2 enzyme-linked immunosorbent assays (ELISAs) run in parallel (Welcozyme, Burroughs Wellcome; and Detect, Biochem Immunosystems). Discordant results were confirmed by Western blot (LiaTek, Organon Technik). Neither ELISA discriminated between HIV-1 and HIV-2. All study participants provided written consent. CD4 cell count measurement was performed in Botswana by FASCount (Becton Dickinson). Patients who had cultures positive for nontuberculous mycobacteria or who did not have an HIV test result or CD4 cell count available were excluded.
Single-component antituberculosis drugs were provided by the Botswana Ministry of Health and were administered by DOT 7 days per week in accordance with Botswana National Tuberculosis Program (BNTP) guidelines [23] . The Botswana Ministry of Health's daily dose guidelines for antituberculosis drugs are outlined in table 1. Patients were hospitalized and fasted for у8 h before witnessed simultaneous ingestion of all antituberculosis drugs. Blood samples were obtained 1, 2, and 6 h after ingestion, and serum was separated and then frozen at Ϫ70ЊC within 1 h after the samples were obtained. Patients were then discharged home to continue antituberculosis treatment as outpatients. In accordance with BNTP guidelines, outpatient treatment entailed daily DOT with 2 months of isoniazid, rifampin, ethambutol, and pyrazinamide therapy followed by 4 months of isoniazid and rifampin therapy, regardless of HIV status [23] .
Frozen serum specimens were transported to National Jewish Medical and Research Center, where pharmacokinetic analyses were performed using validated high-performance liquid chromatography (for isoniazid and rifampin) or gas chromatography (for ethambutol and pyrazinamide) with mass spectrometry. Antituberculosis drug pharmacokinetics for the first 138 patients were analyzed immediately (during 1997-1998); these results are reported elsewhere [22] . Because of logistical and fiscal constraints, immediate pharmacokinetic analysis of all remaining patients' specimens was not possible. Their serum samples were stored frozen (Ϫ70ЊC) at a Centers for Disease Control and Prevention laboratory (Atlanta, GA) until 2006, when additional funding was secured for their analysis. Comparison of drug concentrations obtained during 1997-1998 and those analyzed during 2006 showed no pharmacokinetic differences indicative of specimen degradation. National Jewish Medical and Research Center personnel were blinded to patients' identification and outcome information.
Pharmacokinetics and treatment outcome measurement. Consistent with published reference ranges that were determined and validated worldwide [24] and used in the analysis by Tappero et al. [22] , the maximum serum drug concentration (C max ) in each sample was dichotomized as either normal or low. The values used to define low concentrations were as follows: isoniazid, !3 mg/mL (300-mg dose) or !4 mg/mL (400-mg dose); rifampin (weight-adjusted dose, 450 mg or 600 mg), !8 mg/mL; ethambutol (median dose, 21 mg/kg), !2 mg/mL; and pyrazinamide (median dose, 35 mg/kg), !35 mg/mL. The area under the serum concentration time curve from drug ingestion to final measurement at 6 h (AUC 0-6 h ) was considered as a continuous variable. Isoniazid acetylation was defined as slow if the half-life was у2 h and as fast if the half-life was !2 h (Appendix).
A poor primary treatment outcome was defined as either treatment failure or death during antituberculosis treatment. In accordance with BNTP guidelines, treatment failure was defined as either a sputum smear positive for acid-fast bacilli or a culture positive for mycobacteria at month 5 of tuberculosis treatment or a physician's assessment of unchanged or worsening clinical status at month 6 of treatment, compared with the status at diagnosis. Death during antituberculosis treatment was defined as death due to any cause while receiving antituberculosis medication or within 1 week after stopping tuberculosis treatment. Because of an inability to monitor patients beyond treatment completion, neither relapse nor reinfection was included in our poor treatment outcome definition.
Statistical analysis. Preliminary analyses examined C max and AUC 0-6 h values of individual drugs by treatment outcomes and considered patients' baseline demographic and medical characteristics as potential confounders. Baseline data included detailed patient medical and social history; specific variables included sex, age, prior tuberculosis, smoking status, body mass index, recent diarrhea, chest radiograph findings, tuberculin skin test results, sputum acid-fast bacilli smear and mycobacterial culture results, and results of serologic tests to assess anemia; immune, hepatic, and renal function; and nutritional status.
Additional analyses stratified patients into 3 categories by HIV status and CD4 cell count: (1) HIV uninfected, (2) HIV infected with a CD4 cell count у200 cells/mL, and (3) HIV infected with a CD4 cell count !200 cells/mL. In addition to continuous measures for C max and AUC 0-6 h , we examined drug C max values as dichotomized variables based on high and low concentrations from previously published ranges [25] [26] [27] [28] . Categorical variables were analyzed using a x 2 test or Fisher's exact test when cell sizes were !5 patients. Continuous variables were analyzed using the nonparametric Kruskal-Wallis test to compare distributions. Only variables significantly associated with poor treatment outcome in contingency table analyses were considered for multivariable analysis. Adjustment for potential confounding of the relationship between pharmacokinetic parameters and treatment outcome was performed using a Mantel-Haenszel weighted summary estimate of the risk ratio, with calculation of exact confidence intervals.
was considered P ! .05 to be statistically significant for all analyses.
RESULTS
During the enrollment period, 441 consecutive patients with recently diagnosed tuberculosis were screened for participation in the study. Of these, 157 did not meet all of the eligibility criteria, and 34 refused enrollment (figure 1). The remaining 250 patients gave informed written consent and were enrolled. An additional 21 patients were excluded from the final analysis because of missing HIV status, CD4 cell count, or pharmacokinetic data, and 4 were excluded because nontuberculous mycobacteria were cultured from sputum. Thus, our analysis included 225 patients, 155 (69%) of whom were infected with HIV.
Demographic, diagnostic, and laboratory characteristics of patients are shown in table 2. Fifteen patients (7%) were lost to follow-up before treatment completion. Those lost to followup were demographically and clinically similar to patients for whom treatment outcome was known. Pharmacokinetics. Study patients fasted for a median duration of 12 h before drug ingestion. Fasting time did not differ by HIV status and CD4 cell count category. Moreover, no statistically significant difference was found with regard to doses of antituberculosis drugs administered or the proportion of fast isoniazid acetylators (46%) across HIV status and CD4 cell count categories. Table 3 shows the C max results by HIV status and CD4 cell count category. The median pyrazinamide C max differed across HIV status and CD4 cell count categories ( ; 2 degrees P ! .04 of freedom [df]) and was significantly lower among patients with CD4 cell counts !200 cells/mL, compared with those with CD4 cell counts у200 cells/mL, regardless of whether the patients were infected with HIV ( ; 1 df) or were uninfected P p .03 ( ; 1 df). The median rifampin C max also differed across P p .03 HIV status and CD4 cell count categories ( ; 2 df); how-P ! .04 ever, statistical significance was observed only among HIV-infected patients, for whom the median rifampin C max was lower in those with CD4 cell counts !200 cells/mL than in those with CD4 cell counts у200 cells/mL ( ; 1 df). There were no P p .01 statistically significant differences between HIV-uninfected patients and HIV-infected patients with CD4 cell counts !200 cells/mL ( ; 1 df) or between HIV-uninfected patients P p .17 and HIV-infected patients with CD4 cell counts у200 cells/mL ( ; 1 df). P p . 25 When pharmacokinetic parameters were dichotomized as high and low (see Methods), overall, a low C max of isoniazid was measured in 84 patients (37%), a low C max of rifampin in 188 (84%), a low C max of ethambutol in 87 (39%), and a low C max of pyrazinamide in 11 (5%). The AUC 0-6 h values for several drugs were positively associated with various baseline laboratory characteristics, but none were associated with treatment outcome (data available on request).
Treatment and study outcomes. The distribution of the median number of DOT doses received (a proxy for treatment adherence) was similar across HIV status and CD4 cell count categories (median, 186 doses; range, 32-373 doses). Overall, 36 (17%) of the 210 patients with known or documented outcomes experienced a poor treatment outcome (table 4) .
In contingency table analyses, only low pyrazinamide C max and HIV infection with a CD4 cell count !200 cells/mL were significantly associated with poor treatment outcome (figure 2). The risk of documented poor outcome among patients with low pyrazinamide C max was 3 times greater than the risk of poor outcome among patients with normal pyrazinamide levels (50.0% vs. 15.7%;
). The risk of poor treatment outcome P ! .01 figure 2B ). No P p .01 other demographic, laboratory, or pharmacokinetic variables were significantly associated with poor treatment outcome. Figure 3 depicts the relationship between treatment outcome and antituberculosis drug C max values. In general, the upper ranges of C max values were higher for patients with good treatment outcomes than for patients with poor treatment outcomes. Kruskal-Wallis analysis demonstrated that only pyrazinamide C max values differed significantly by treatment outcome ( ); results for other antituberculosis drug con-P p .03 centrations were not statistically significant (isoniazid, P p ; rifampin, ; ethambutol, ). .59 P p .32 P p .45 Because the median pyrazinamide C max differed significantly by HIV status and CD4 cell count category and pyrazinamide C max and HIV status and CD4 cell count categories were associated with treatment outcome, we examined the risk ratio for poor outcome for low versus normal pyrazinamide C max across HIV status and CD4 cell count categories (table 5). The risk ratio estimates for low pyrazinamide C max were similar across HIV status and CD4 cell count categories. The association between low pyrazinamide C max and poor treatment outcome was strongest (risk ratio, 4.06; 95% confidence interval, 2.72-6.06) among patients who were HIV infected with CD4 cell counts !200 cells/mL, although the differences across HIV status and CD4 cell count categories were not statistically significant (homogeneity, ). The Mantel-Haenszel sum-P p .61 mary risk ratio for low pyrazinamide C max across HIV status and CD4 cell count categories was 3.38 (95% confidence interval, 1.84-6.22).
DISCUSSION
In the present study, poor treatment outcomes occurred in ∼1 (17%) of 6 adult patients with pulmonary tuberculosis, despite administration of standard antituberculosis drug dosages through daily DOT. The failure of global tuberculosis control strategies such as DOTS to guarantee good treatment outcomes in certain populations is multifactorial. Our data suggest that ; 1 df), and HIV-infected patients with CD4 cell count у200 cells/mL versus HIV-uninfected patients P p .01 ( ; 1 df). P p .81 low blood pyrazinamide concentrations may contribute to poor treatment outcomes in resource-limited settings with a high prevalence of HIV infection.
Although infrequent, we found that low pyrazinamide C max values were associated with increased risk of poor treatment outcome among patients with tuberculosis, regardless of HIV infection status. Low C max values for antituberculosis drugs, particularly for rifampin, have been documented previously and have been postulated to influence treatment outcome and/or acquired drug resistance [7] [8] [9] [10] 17] . To our knowledge, however, this is the first study linking low pyrazinamide C max with poor treatment outcome. The reason for pyrazinamide's possible relationship to treatment outcome may reflect its presumed antimycobacterial effects. In contrast to most other antituberculosis drugs, pyrazinamide's ability to sterilize tissues enables routine treatment to be 6 months instead of 9-12 months [29, 30] . The exact mechanism by which this effect occurs is not known, but the failure to reach a sufficiently high concentration to achieve sterilization may account for the higher risk of treatment failure and death observed. Another possible explanation for our findings is that, because pyrazinamide has been shown to have minimal absorption variability relative to other first-line antituberculosis drugs [31] , it would be more likely to influence treatment outcomes. Although our sample size was large relative to similar pharmacokinetic studies, its statistical power may be insufficient to reveal any associations between the more variably absorbed nonpyrazinamide antituberculosis drugs and treatment outcome. Finally, pyrazinamide has also been shown to have a synergistic relationship with rifampin [32] .
Despite the fact that most study patients completed treatment or were cured, even while experiencing lower than expected C max values, persistently low drug concentrations could still facilitate the development of drug-resistant M. tuberculosis. As treatment progresses, patients may have an increased risk for developing resistance to antituberculosis drugs for which their serum concentrations are low, manifesting as delayed smear conversion, treatment failure, or relapse. Unfortunately, we could not address these questions, because drug susceptibility testing was not performed for patients who continued to have positive culture results after 6 months of treatment, and additional drug concentrations were not measured throughout tuberculosis treatment.
Factors that influence antituberculosis drug pharmacokinet- ics continue to be identified, many of which occur simultaneously (e.g., gastrointestinal infections and HIV infection) or are unavoidable (e.g., sex, age, and isoniazid acetylator phenotype). It is almost certain that, once patients are in the home environment, their antituberculosis drug pharmacokinetic profiles are significantly different from those measured in controlled clinical trials [25] [26] [27] [28] . In this study, we measured drug pharmacokinetics early during treatment, under ideal conditions (i.e., monitored and fasting), and at a point during treatment when a pharmacokinetic steady state had been reached. Thus, our findings may actually underestimate the true frequency at which pharmacokinetic aberrations occurred once participants returned home. Performance of therapeutic antituberculosis drug monitoring throughout treatment would have addressed this question; however, because of expense and limited access, such monitoring is not commonly performed in resource-limited nations. Another option to ensure antituberculosis drug pharmacokinetic goals is to increase standard drug doses for patients at risk of lower than expected levels. However, adverse effects have typically limited the extent to which this can safely occur. Therefore, the fundamental question may be, are current antituberculosis drug doses and pharmacokinetic norms applicable to outpatients and persons with HIV infection and AIDS specifically and across global populations generally? Other investigators have already raised this question [13] .
This study has several important limitations. First, relatively few patients had low pyrazinamide C max values, and small frequency changes would have had important statistical consequences. As such, our findings require further investigation. However, this study is among the largest to date that specifically examined antituberculosis drug pharmacokinetics and treatment outcomes. Second, antiretrovirals were not widely available in Botswana during the study period; many participants met the criteria for having AIDS and likely experienced morbidity and mortality attributable to their HIV infection. Because autopsies were not performed on decedents, misclassification bias and overestimation of tuberculosis-attributed outcomes may have occurred. However, the relationship between low pyrazinamide concentration and poor treatment outcome was observed for each strata of HIV status and CD4 cell count and, thus, was not limited to HIV-related deaths. Moreover, our definitions of death during treatment and the composite unsuccessful or poor treatment outcome are in accordance with World Health Organization guidelines [33] . Third, the treatment failure rate that we observed exceeded rates reported in similar populations [16, 17, 34] . DOT eliminates nonadherence to treatment as a possible cause, but substandard antituberculosis drug quality and/or laboratory smear processing errors cannot be ruled out. Fourth, because our study did not rely solely on culture-confirmed cure for a designation of good treatment outcome, its findings might not be directly comparable to other studies that define treatment outcome on the basis of culture confirmation. Finally, we measured antituberculosis drug pharmacokinetics only once during antituberculosis treatment, and patients' pharmacokinetic profiles may have changed as their health status changed. This study was not designed to determine the specific causes (e.g., malabsorption) of observed pharmacokinetic aberrations, only their epidemiologic associations.
Tuberculosis disables and kills millions of people every year, and HIV infection and antituberculosis drug resistance threaten to reverse decades of tuberculosis control progress. Chemotherapy regimens against M. tuberculosis infection are a vital component of tuberculosis elimination strategies, but our study is a reminder that their effectiveness should not be taken for granted. This study also indicates a need to reexamine pyrazinamide's role in antituberculosis treatment and whether treatment should be extended to 9 months for persons with HIV infection with CD4 cell counts !200 cells/mL. The standard antituberculosis treatment regimens established before the HIV epidemic may simply not be effective for all individuals, particularly those most at risk of tuberculosis today (i.e., people in resource-limited settings and those infected with HIV). We encourage others to investigate norms of antituberculosis drug pharmacokinetics in diverse populations and, particularly, in people living with HIV who are receiving or not receiving antiretroviral therapy.
